Dihydrotestosterone, almost always abbreviated as DHT, is the single most important hormone in the biology of pattern hair loss. It is also one of the most consistently misunderstood. People sometimes describe it as a hormone that "kills" hair follicles, or as a sign that something has gone wrong with the body's hormone levels. Neither is accurate. DHT is a normal androgen, present in everyone in varying amounts, with important roles in development and physiology. The reason it causes hair loss in some people and not others has very little to do with how much DHT is circulating, and almost everything to do with how individual follicles are genetically wired to respond to it.
This guide explains what DHT actually is at a biochemical level, where it comes from, why it is more potent than testosterone at the receptor, and what makes scalp follicles in some men and women uniquely sensitive to its signal. It also covers why DHT inhibition with medications like finasteride and dutasteride helps slow or partially reverse the process, and why those medications take months to show their effect. The goal is to give you a working model of the hormone that is durable and accurate, rather than a simplified version that has to be unlearned later.
Testosterone, DHT, and the difference between them
Testosterone is the better-known of the two androgens. It is produced primarily in the testes in men and in smaller amounts by the ovaries and adrenal glands in women. Testosterone is the hormone responsible for many of the physical changes of male puberty, for the maintenance of muscle mass and bone density, and for a wide range of other effects on metabolism and mood. It circulates in the bloodstream and is delivered to tissues throughout the body.
DHT is a metabolite of testosterone. It is produced when the enzyme 5-alpha-reductase removes a double bond at the 4,5 position of the testosterone steroid ring. The product, 5-alpha-dihydrotestosterone, is structurally similar to testosterone but with two important differences in how it behaves at the androgen receptor. DHT binds to the androgen receptor with roughly two to three times the affinity of testosterone, and it dissociates more slowly. The net result is that DHT delivers a stronger and more sustained androgenic signal to any cell that expresses the receptor.
This is why DHT is sometimes described as the "active" form of testosterone in certain tissues. In the prostate, in the genital skin, in the beard area, and in the scalp, much of the androgenic effect is mediated by DHT rather than by testosterone itself. The amplification provided by 5-alpha-reductase is part of how the body fine-tunes androgen signaling in tissues that need a stronger response than circulating testosterone alone would provide.
Where DHT comes from in the body
DHT is produced wherever 5-alpha-reductase is expressed. There are two main isoenzymes, called Type I and Type II, encoded by separate genes (SRD5A1 and SRD5A2) and distributed differently across tissues.
Type II 5-alpha-reductase is concentrated in the prostate, the genital skin, the seminal vesicles, and the dermal papillae of hair follicles, including the genetically susceptible follicles of the scalp. It is the dominant isoenzyme in male genital development and a major contributor to scalp DHT in adults.
Type I 5-alpha-reductase has a broader distribution, including the sebaceous glands of the skin, the liver, certain areas of the central nervous system, and adipose tissue. It contributes to circulating DHT levels and to local DHT in skin and other peripheral tissues.
A third isoform, Type III (SRD5A3), has been described more recently. It is expressed widely but plays a smaller role in the conversion of testosterone to DHT compared with Types I and II.
This division matters clinically because the two main 5-alpha-reductase inhibitor medications target the isoenzymes differently. Finasteride is a selective inhibitor of Type II, with some activity at Type III. Dutasteride is a non-selective inhibitor that suppresses both Type I and Type II. The result is that dutasteride lowers serum and scalp DHT more profoundly than finasteride does, which is one reason it is sometimes considered for patients who do not respond adequately to finasteride alone. We compare them in detail in finasteride versus dutasteride and how dutasteride treats hair loss.
Why DHT binds the androgen receptor more tightly
The androgen receptor is a protein expressed inside many cell types. When testosterone or DHT enters the cell and binds to the receptor, the receptor undergoes a conformational change, translocates to the nucleus, and begins regulating the transcription of androgen-responsive genes. The downstream effects depend on what genes a particular cell type expresses and on the local context.
DHT binds the androgen receptor with two to three times the affinity of testosterone, and the dissociation rate is roughly half. In practical terms, a DHT molecule that has bound to a receptor stays bound for longer, occupying the receptor and continuing to drive gene expression. This is why a small amount of DHT can produce a stronger biological effect than a much larger amount of testosterone in the same tissue.
The implication for hair follicles is direct. Even modest local conversion of testosterone to DHT in the dermal papilla can sustain a powerful androgenic signal at the receptor, which then drives the gene expression changes that compress the hair growth cycle.
Androgen receptor density and genetic sensitivity
The amount of DHT in the bloodstream is not, on its own, what determines whether someone will develop pattern hair loss. Two men can have similar circulating DHT levels and very different hair outcomes. The variable that explains most of the difference is the sensitivity of the follicle to the hormone, and that sensitivity is largely genetic.
The androgen receptor is encoded by the AR gene, which sits on the X chromosome. Variants in the AR gene, particularly in the regulatory region that controls its expression, influence how much androgen receptor protein is produced in androgen-responsive tissues. Genome-wide association studies have consistently identified AR locus variants as among the strongest genetic risk factors for androgenetic alopecia. Other genes have been implicated as well, in pathways related to androgen metabolism, Wnt signaling, and follicle development, but AR is the most robust and best-replicated finding.
Because AR is X-linked, the maternal grandfather has often been described as a useful reference point for hair loss risk in men. The reality is more complicated, since multiple genes contribute and inheritance is polygenic, but the X-linked component remains an important part of why pattern hair loss tends to run in families.
The follicle's local environment also matters. Follicles in the temple, frontal hairline, and crown express more androgen receptors and more 5-alpha-reductase Type II than follicles in the occipital scalp at the back of the head. This is why the back and sides typically remain dense even in advanced androgenetic alopecia, and why hair from those donor zones can be transplanted into the thinning areas without losing its resilience: the donor follicles carry their relative insensitivity with them.
How DHT actually causes hair loss
When DHT binds the androgen receptor in a genetically sensitive scalp follicle, the receptor drives a series of changes in the dermal papilla. The most important of these is a progressive shortening of the anagen phase, which is the active growth phase of the hair cycle. Anagen, which normally lasts two to seven years on the scalp, is compressed over many cycles to months and eventually weeks. Each successive hair produced by the follicle is shorter, thinner, and lighter than the one before. This process is called follicle miniaturization.
The cellular mechanisms behind miniaturization are still being characterized, but several pathways have been identified. DHT-bound androgen receptors influence the expression of TGF-beta, dickkopf-1 (DKK-1), and other signaling molecules that promote catagen entry. The dermal papilla itself shrinks, with fewer cells and reduced production of growth-supportive factors. The follicle does not die immediately. It cycles, but each cycle produces less hair than the last, and the proportion of follicles in any given area that are in productive anagen at any moment falls.
The clinical consequence is the pattern that gives the condition its name. In men, the temples recede, the frontal hairline retreats, and the crown thins, while the lateral and occipital scalp remain relatively dense. In women, the pattern is more often diffuse thinning along the central part with preservation of the frontal hairline, though the variation is significant. We describe these patterns in detail under stages and at /hair-loss/dht.
It is worth emphasizing that this is a chronic, progressive process. Without intervention, the cycle continues to shorten and the proportion of miniaturized follicles increases over years and decades. Periods of stability can occur, but the overall trajectory in untreated androgenetic alopecia is gradual progression.
Why DHT inhibition helps
Because DHT is the proximate hormonal driver of follicle miniaturization in pattern hair loss, lowering DHT, particularly local DHT in the scalp, removes much of the pressure on the cycle. Finasteride and dutasteride both work this way.
Finasteride, taken orally at 1 mg per day for hair loss, inhibits 5-alpha-reductase Type II and reduces serum DHT by roughly 60 to 70 percent. Scalp DHT falls by a similar magnitude. Over months, the cycle response in androgen-sensitive follicles begins to lengthen again, miniaturized follicles produce thicker hairs, and the visible appearance of density may improve. Most clinical trials show benefit becoming visible at three to six months, with the most meaningful change between six and twelve months. The medication does not eliminate DHT, and it does not cure androgenetic alopecia. It modifies the hormonal environment enough that the cycle can partially recover. We cover the medication in depth in how finasteride treats hair loss.
Dutasteride is a non-selective 5-alpha-reductase inhibitor that suppresses both Type I and Type II isoenzymes, lowering serum DHT by more than 90 percent. It is FDA-approved for benign prostatic hyperplasia in the United States and is used off-label for hair loss in some patients, particularly those who have not responded adequately to finasteride. The clinical data for hair loss is generally favorable but smaller in volume than for finasteride, and the medication is generally considered when finasteride has been insufficient.
Topical formulations of finasteride and dutasteride exist as well, and may be appropriate for some patients under physician supervision when systemic exposure is a concern. The choice between oral and topical, and between finasteride and dutasteride, is one that should be made with a clinician who can take into account the full clinical picture.
For comparison with minoxidil, which works on a different part of the cycle, see minoxidil versus finasteride. The two are often used together because they target distinct mechanisms.
What DHT inhibition does not do
A few clarifications are worth making to avoid common misconceptions.
DHT inhibition does not regrow follicles that have been lost. Once a follicle has progressed past the late stages of miniaturization and ceased to cycle, no current oral medication can recreate it. This is part of why earlier intervention generally produces more meaningful results than waiting until significant density has been lost.
DHT inhibition does not halt aging-related changes in the hair. Some thinning that occurs with age is independent of androgens and is not pharmacologically reversible.
DHT inhibition is not always effective. A subset of patients respond minimally, and some may have hair loss driven by mechanisms other than androgens. A careful clinical evaluation is the appropriate first step, particularly when the pattern is atypical or the shedding is sudden.
5-alpha-reductase inhibitors also have potential side effects, including effects on libido, erectile function, mood, and post-treatment persistence in a small subset of patients. These are generally uncommon and frequently reversible on discontinuation, but they are real and should be discussed with a physician before starting treatment. Treatment decisions should be individualized and made under physician supervision.
How long the effect takes to appear and to fade
Because DHT inhibition acts on the hair cycle, and because the cycle is measured in months to years, the effect of finasteride or dutasteride is slow to develop. Most patients see no visible change in the first one to three months. Modest stabilization is often apparent at three to six months. The most meaningful improvements typically emerge between six and twelve months, with continued gradual change up to eighteen months. We discuss the timeline in more detail in how long hair loss treatment takes.
The reverse is also true. If treatment is stopped, scalp DHT levels return to baseline within weeks, and the cycle gradually drifts back toward its untreated state over the subsequent six to twelve months. The follicles do not "remember" that they had been treated, and any gains that depended on continuous DHT suppression will be lost. This is discussed at what happens if you stop treatment.
Putting it together
DHT is a natural androgen, more potent than testosterone at the androgen receptor, produced from testosterone by 5-alpha-reductase isoenzymes that are expressed across many tissues including the scalp. Pattern hair loss is not caused by abnormally high DHT in most people. It is caused by genetically determined sensitivity in scalp follicles, where the androgen receptor responds to normal levels of DHT by progressively shortening the hair growth cycle and miniaturizing the follicle. Medications that lower DHT can partially reverse this process, but they do so over months and they require continued use to maintain the effect.
If you understand DHT in those terms, much of the rest of the pattern hair loss conversation falls into place. The reason treatments take time, the reason they have to be ongoing, the reason some areas of the scalp are affected and others are not, and the reason different family members can have very different outcomes are all consequences of the same underlying biology. Treatment decisions become clearer when the mechanism is clear, and conversations with your physician become more productive.
